Aging might not be inevitable.

In this episode of Decoding Longevity, Dr. Michael Ringel (COO, Life Biosciences) explains how scientists are learning to “reset” the biological age of cells—without changing what they are.

From reversing vision loss in preclinical models to launching one of the first human trials, this conversation explores a future where we don’t just treat diseases of aging—we target aging itself.

🔗 Show notes:

• Life Biosciences: https://www.lifebiosciences.com/

• Clinical pipeline: https://www.lifebiosciences.com/pipeline/

• Michael Ringel talks: https://www.youtube.com/watch?v=XC31N9KbOEs / https://www.youtube.com/watch?v=OycGR-03S8A / https://www.youtube.com/watch?v=EZUBjXv5wIw

What if aging isn’t defined by disease — but by how much function we preserve over time?

In this episode of Decoding Longevity, Raghav Sehgal and Macsue Jacques sit down with Stephen Kritchevsky to explore how mobility, metabolism, and physiological resilience shape the aging process.

From walking speed as a powerful integrative biomarker… to why muscle quality may matter more than muscle mass… to what long-term trials like Look AHEAD reveal about bending aging trajectories — this conversation reframes longevity around function, not just lifespan.

We also dive into the trade-offs of weight loss in older adults, the connection between brain and physical aging, and what it will take to measure — and truly slow — aging in humans.

What if the biggest barrier to extending healthy human lifespan isn’t the science — but policy?

In this episode of Decoding Longevity, hosts Raghav Sehgal and Macsue Jacques speak with Dylan Livingston, founder of the Alliance for Longevity Initiatives. Together, they explore why public policy may be one of the most important — and overlooked — drivers of progress in longevity science.

From building support for aging research funding to launching the Congressional Longevity Science Caucus and expanding access to investigational therapies, Dylan shares how advocacy and legislation could shape the future of preventative medicine and healthy aging.

Learn more:

Alliance for Longevity Initiatives (A4LI) → https://a4li.org/

LongeviPAC → https://www.longevipac.org/

What if the future of medicine is preventing aging-related disease before it begins?

In this episode of Decoding Longevity, Raghav Sehgal and Macsue Jacques speak with James Peyer, CEO of Cambrian Biopharma, about turning aging biology into real therapeutics.

We explore exercise-mimetic drugs, metabolism reset therapies, mTOR inhibition, and the path to the first approved gerotherapeutics.

In this episode of Decoding Longevity, host Raghav Sehgal and co-host Macsue Jacques explore one of the most powerful — and often overlooked — drivers of aging: the immune system.

Joined by immunologist Alan Landay, the conversation uncovers how chronic inflammation — often described as inflammaging — shapes biological aging at the cellular level. Drawing on decades of HIV research, Dr. Landay explains how persistent immune activation, gut barrier dysfunction, and microbiome imbalance contribute to age-related diseases long before symptoms appear.

The episode dives into:

• Why aging is a biological process — not just the passage of time

• How immune dysregulation accelerates cardiovascular and metabolic disease

• The role of gut health and microbial metabolites in systemic inflammation

• Biological aging clocks and emerging biomarkers

• Promising interventions — from lifestyle strategies to immune-targeted therapies

This conversation reframes aging as an immune-driven process and highlights how understanding inflammation may be key to extending healthspan.

In this episode of Decoding Longevity, hosts Raghav Sehgal and Macsue Jacques are joined by Dr. Karl Pfleger — angel investor, longevity industry analyst, and creator of AgingBiotech.info.

We explore the rapidly growing aging biotech ecosystem, including:

• Repairing aging vs. slowing aging

• Rejuvenation biotech and combination therapies

• Longevity investing, biomarkers, and regulation

• Why ecosystems matter in aging research
  

A big-picture conversation on longevity science, rejuvenation, and the future of aging as a biological problem.

What if healthy longevity depends not only on your DNA, but on the city you live in, the air you breathe, and the communities you’re part of?

In this episode, Raghav Sehgal and Macsue Jacques talk with Tina Woods — CEO of Collider Health and leading voice of the Human Exposome Project — about how environmental, social and lifestyle exposures shape aging.

You’ll learn:

• What the human exposome is and why it drives most health outcomes

• How cities, neighborhoods & clinics can become “living labs” for aging research

• How exposome data links with methylation, inflammation & aging biomarkers

• Why future longevity breakthroughs rely on policy, environment & community design

• The role of trust, data governance & public engagement in healthy longevity

👇 Links

Collider Health: https://www.colliderhealth.com/

Human Exposome Project paper: https://www.nature.com/articles/s41591-025-03519-8

🎙️ Hosts: Raghav Sehgal & Macsue Jacques

Follow for more conversations on aging, healthspan & prevention.

What if we could produce safe, ethical, and infinitely renewable stem cells — without relying on embryos or complex reprogramming? In this episode, Raghav Sehgal and Macsue Jacques sit down with Yuta Lee, Founder and CEO of Accelerated Biosciences, to explore how his team is pioneering a new source of true pluripotent stem cells that could transform regenerative medicine and longevity research.

We dive into:

• How Accelerated Biosciences discovered its unique stem cell line

• Why these cells could bypass major ethical and regulatory barriers

• The potential to treat age-related diseases at their cellular roots

• How this technology could redefine “longevity therapeutics”

👉 Tune in to learn how biology and biotechnology are converging to reshape the future of healthcare and human lifespan.

🔗 Learn more about Accelerated Biosciences: https://www.acceleratedbio.com/

What if cardiovascular disease wasn’t just about high cholesterol — but about a toxic, oxidized form that drives plaque buildup and cellular dysfunction?

In this episode, hosts Raghav Sehgal and Macsue Jacques talk with Matthew “Oki” O’Connor, a leading researcher exploring how 7-ketocholesterol fuels atherosclerosis — and how a new therapeutic candidate could reverse aspects of this age-related disease.

We dive into:

💡 What makes 7-ketocholesterol so harmful

🔬 How targeting it can transform foam cells back into healthy macrophages

💊 How this approach differs from statins and traditional lipid-lowering therapies

🌏 Early trials launching in Australia

⏳ The future of cardiovascular rejuvenation and healthy aging

If you’re interested in how cutting-edge science could reshape the fight against cardiovascular aging, this episode is for you.

🎧 Listen now and explore how targeting oxidized cholesterol might help us decode longevity.

What if aging research didn’t just happen in labs but through a global community of people contributing their data and testing interventions in real time?

In this episode, hosts Raghav Sehgal and Macsue Jacques talk with Jasmine Smith, CEO of Rejuve.AI, about how Decentralized Science (DeSci), AI, and n-of-1 trials are transforming personalized longevity research.

👉 Learn more about Rejuve.AI: https://www.rejuve.ai/